GP9

Across TCGA pan-cancer cohorts, GP9 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GP9 data layer compared with 21 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GP9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GP9 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD, LSCC, and GBM are the cancer types where GP9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.325	0.874	.026	6	view →
LSCC	DFS	Median	All	0.912	0.460	.007	6	view →
GBM	OS	Quartile	All	0.319	0.687	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GP9–LUAD (DFS)

Open the LUAD breakdown →